Institutional investors are reshuffling portfolios with large block deals in Gland Pharma and Meesho, while infrastructure companies Power Grid and Rail Vikas Nigam announce significant new project wins. Meanwhile, Cipla is expanding its US biosimilar portfolio, even as RBL Bank faces a new tax demand notice.
The Indian market is witnessing a busy period marked by large institutional sell-offs and new infrastructure project wins. Investors are currently evaluating the impact of significant stake sales in the pharmaceutical and technology sectors, alongside positive order book updates for major utility and rail companies.
Institutional Block Deals
Significant institutional activity is driving volatility in specific stocks today. Fosun Pharma Industrial is moving to sell a 5% stake in Gland Pharma. The transaction, executed through a block deal, is priced at a floor price of ₹2,763 per share, with a total value of approximately ₹2,279.5 crore. Such large divestments by major shareholders often lead to short-term price adjustments as the market absorbs the new supply of shares.
In the technology sector, SoftBank’s SVF II Meerkat has completed the sale of a 1.73% stake in the e-commerce firm Meesho. The deal fetched roughly ₹1,650.4 crore, attracting interest from major financial institutions including Morgan Stanley, Fidelity, and Goldman Sachs. This movement signals a shift in the cap table for the unlisted tech major.
Infrastructure and Strategic Wins
Infrastructure and utility stocks remain in focus following fresh contract announcements. Power Grid Corporation of India has secured a Letter of Intent for a transmission project in Gujarat valued at ₹1,152.49 crore. The project is designed to integrate 7,500 MW of renewable energy into the grid, highlighting the company’s role in the national green energy transition. Similarly, Rail Vikas Nigam has been declared the lowest bidder (L1) for a contract from East Coast Railway worth ₹404.88 crore, reinforcing its consistent order flow in the railway segment.
Corporate Developments and Regulatory Risks
In the pharmaceutical sector, Cipla continues to broaden its global reach. Its subsidiary, Invagen Pharmaceuticals, has formed a strategic partnership with Qilu Pharmaceutical. The collaboration focuses on the US market, specifically for the supply and licensing of a biosimilar for Keytruda, an oncology drug. This move aligns with the company’s strategy to strengthen its position in the competitive high-value biosimilars segment.
On the regulatory front, RBL Bank is managing a new challenge. The bank has received a show-cause notice from the Assistant Commissioner in Delhi regarding a GST demand of ₹164.13 crore. The tax authorities have linked this demand to alleged input tax credit mismatches in the bank’s bullion business for the 2022-23 fiscal year. The bank is currently contesting the matter, and investors will be monitoring the final resolution, as unexpected tax liabilities can impact net earnings.
Other notable developments include Avalon Technologies establishing a joint venture with Germany’s Zollner Elektronik AG to improve domestic electronics manufacturing. Sterlite Technologies has planned a ₹3,000 crore capital expenditure to meet global demand for optical fiber. Additionally, Ramco Systems has partnered with Safran Helicopter Engines to integrate advanced data analytics into its aviation software, and Shanthi Gears has appointed Sai Krishna Alluri as its new Chief Financial Officer.